SG11201910027YA - Bispecific antibody against ox40 and ctla-4 - Google Patents
Bispecific antibody against ox40 and ctla-4Info
- Publication number
- SG11201910027YA SG11201910027YA SG11201910027YA SG11201910027YA SG 11201910027Y A SG11201910027Y A SG 11201910027YA SG 11201910027Y A SG11201910027Y A SG 11201910027YA SG 11201910027Y A SG11201910027Y A SG 11201910027YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- medicon
- lund
- village
- alligator
- Prior art date
Links
- MISZALMBODQYFT-URVXVIKDSA-N 125-69-9 Chemical compound Br.C([C@@H]12)CCC[C@]11CCN(C)[C@H]2CC2=CC=C(OC)C=C21 MISZALMBODQYFT-URVXVIKDSA-N 0.000 abstract 5
- 241000270728 Alligator Species 0.000 abstract 5
- 102000008203 CTLA-4 Antigen Human genes 0.000 abstract 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 abstract 2
- 229940045513 CTLA4 antagonist Drugs 0.000 abstract 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 abstract 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- LFEUVBZXUFMACD-UHFFFAOYSA-H lead(2+);trioxido(oxo)-$l^{5}-arsane Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-][As]([O-])([O-])=O.[O-][As]([O-])([O-])=O LFEUVBZXUFMACD-UHFFFAOYSA-H 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 November 2018 (08.11.2018) WIPO I PCT (51) International Patent Classification: C07K 16/28 (2006.01) A61K 39/00 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/EP2018/061084 (22) International Filing Date: 01 May 2018 (01.05.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1706915.4 02 May 2017 (02.05.2017) GB 1717958.1 31 October 2017 (31.10.2017) GB 1805873.5 09 April 2018 (09.04.2018) GB (71) Applicant: ALLIGATOR BIOSCIENCE AB [SE/SE]; Medicon Village, SE-233 81 Lund (SE). (72) Inventors: ELLMARK, Peter; Alligator Bioscience AB, Medicon Village, SE-233 81 Lund (SE). FUREBRING, Christina; Alligator Bioscience AB, Medicon Village, SE-233 81 Lund (SE). NORLEN, Per; Alligator Bio- science AB, Medicon Village, SE-233 81 Lund (SE). VEI- TONMAKI, Niina; Alligator Bioscience AB, Medicon Village, SE-233 81 Lund (SE). (74) Agent: SMITH, Stephen Edward; Potter Clarkson LLP, The Belgrave Centre, Talbot Street, Nottingham NG1 5GG (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: BISPECIFIC ANTIBODY AGAINST OX40 AND CTLA-4 - (57) : The present invention provides bispecific polypeptides, such as bispecific antibodies, comprising a first binding domain = capable of specifically binding to OX40, and a second binding domain capable of specifically binding to CTLA-4. The invention further — provides compositions of said bispecific polypeptides, as well as methods and uses of the same. ill 1111u°111110111sOHo o Holonomioomnium (10) International Publication Number WO 2018/202649 Al W O 20 18/ 20 26 49 Al [Continued on next page] WO 2018/202649 Al 0 111 Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1706915.4A GB201706915D0 (en) | 2017-05-02 | 2017-05-02 | Novel polypeptides |
| GBGB1717958.1A GB201717958D0 (en) | 2017-10-31 | 2017-10-31 | Novel polypeptides |
| GBGB1805873.5A GB201805873D0 (en) | 2018-04-09 | 2018-04-09 | Novel polypeptides |
| PCT/EP2018/061084 WO2018202649A1 (en) | 2017-05-02 | 2018-05-01 | Bispecific antibody against ox40 and ctla-4 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201910027YA true SG11201910027YA (en) | 2019-11-28 |
Family
ID=62186395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201910027Y SG11201910027YA (en) | 2017-05-02 | 2018-05-01 | Bispecific antibody against ox40 and ctla-4 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20200048358A1 (en) |
| EP (1) | EP3619236A1 (en) |
| JP (1) | JP2020518622A (en) |
| KR (1) | KR20200002889A (en) |
| CN (1) | CN110709421A (en) |
| AU (1) | AU2018262156A1 (en) |
| BR (1) | BR112019023097A2 (en) |
| CA (1) | CA3061549A1 (en) |
| MX (1) | MX2019012953A (en) |
| RU (1) | RU2019138067A (en) |
| SG (1) | SG11201910027YA (en) |
| WO (1) | WO2018202649A1 (en) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018041119A1 (en) | 2016-08-31 | 2018-03-08 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric ox40 |
| CN107815465B (en) * | 2016-08-31 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | Preparation method and application of humanized gene modified animal model |
| PT3551660T (en) | 2016-12-07 | 2023-11-30 | Ludwig Inst For Cancer Res Ltd | Anti-ctla-4 antibodies and methods of use thereof |
| CN111511762A (en) | 2017-08-21 | 2020-08-07 | 天演药业公司 | anti-CD137 molecules and uses thereof |
| WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| JP2022513432A (en) * | 2018-11-13 | 2022-02-08 | ジェイエヌ バイオサイエンシーズ エルエルシー | Bispecific antibodies for immune cell activation |
| TWI793395B (en) * | 2019-01-25 | 2023-02-21 | 大陸商信達生物製藥（蘇州）有限公司 | Bispecific antibodies that bind to pd-l1 and ox40 |
| US20240141070A1 (en) * | 2019-10-17 | 2024-05-02 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd. | Ox40/pd-l1 bispecific antibody |
| US20240117053A1 (en) * | 2019-10-17 | 2024-04-11 | Regents Of The University Of Minnesota | Clec12a antibody fragment sequences and methods |
| WO2021098851A1 (en) * | 2019-11-20 | 2021-05-27 | Eucure (Beijing) Biopharma Co., Ltd | Anti-ctla4/ox40 bispecific antibodies and uses thereof |
| IL294557A (en) | 2020-01-07 | 2022-09-01 | Univ Texas | Improved human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy |
| AU2021264838A1 (en) | 2020-04-26 | 2022-10-27 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Modified immunoglobulins |
| TWI802923B (en) * | 2020-06-30 | 2023-05-21 | 大陸商和鉑醫藥（上海）有限責任公司 | Antibody targeting OX40 and its preparation method and application |
| WO2022002065A1 (en) * | 2020-06-30 | 2022-01-06 | 百奥泰生物制药股份有限公司 | Anti-cd40 antibody or antigen-binding fragment and use thereof |
| WO2022117572A2 (en) | 2020-12-02 | 2022-06-09 | Oncurious Nv | An ltbr agonist in combination therapy against cancer |
| CN114085376B (en) * | 2021-12-02 | 2022-12-20 | 中国科学院长春应用化学研究所 | Polypeptide, preparation method thereof, bispecific antibody and application thereof |
| AU2022411573A1 (en) * | 2021-12-17 | 2024-06-27 | Shanghai Henlius Biologics Co., Ltd. | Anti-ox40 antibodies and methods of use |
| EP4448578A1 (en) * | 2021-12-17 | 2024-10-23 | Shanghai Henlius Biotech, Inc. | Anti-ox40 antibodies, multispecific antibodies and methods of use |
| WO2023143478A1 (en) * | 2022-01-27 | 2023-08-03 | Crown Bioscience Inc. | Novel anti-cd4 and anti-pd-l1 bispecific antibodies |
| CN118541390A (en) * | 2022-01-30 | 2024-08-23 | 百奥赛图(北京)医药科技股份有限公司 | Anti-CTLA 4/OX40 bispecific antibodies and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EE05627B1 (en) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | Human monoclonal antibodies to CTLA-4 |
| EP2626372B1 (en) | 2007-03-29 | 2018-03-21 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| PT2560993T (en) | 2010-04-20 | 2024-09-16 | Genmab As | Heterodimeric antibody fc-containing proteins and methods for production thereof |
| GB201311475D0 (en) | 2013-06-27 | 2013-08-14 | Alligator Bioscience Ab | Polypeptides |
| MA39502A (en) * | 2014-02-28 | 2015-09-03 | Glenmark Pharmaceuticals Sa | EXPRESSIONAL CONSTRUCTIONS AND METHODS OF SELECTING HOST CELLS EXPRESSING POLYPEPTIDES |
| JP2018520650A (en) * | 2015-05-21 | 2018-08-02 | アリゲーター・バイオサイエンス・アーベー | Novel polypeptide |
-
2018
- 2018-05-01 RU RU2019138067A patent/RU2019138067A/en unknown
- 2018-05-01 CA CA3061549A patent/CA3061549A1/en not_active Abandoned
- 2018-05-01 AU AU2018262156A patent/AU2018262156A1/en not_active Abandoned
- 2018-05-01 EP EP18725117.8A patent/EP3619236A1/en not_active Withdrawn
- 2018-05-01 KR KR1020197032700A patent/KR20200002889A/en unknown
- 2018-05-01 US US16/607,774 patent/US20200048358A1/en not_active Abandoned
- 2018-05-01 CN CN201880036552.4A patent/CN110709421A/en active Pending
- 2018-05-01 SG SG11201910027Y patent/SG11201910027YA/en unknown
- 2018-05-01 MX MX2019012953A patent/MX2019012953A/en unknown
- 2018-05-01 WO PCT/EP2018/061084 patent/WO2018202649A1/en unknown
- 2018-05-01 BR BR112019023097-1A patent/BR112019023097A2/en not_active Application Discontinuation
- 2018-05-01 JP JP2019560265A patent/JP2020518622A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018202649A1 (en) | 2018-11-08 |
| MX2019012953A (en) | 2020-02-12 |
| CN110709421A (en) | 2020-01-17 |
| RU2019138067A (en) | 2021-06-02 |
| JP2020518622A (en) | 2020-06-25 |
| US20200048358A1 (en) | 2020-02-13 |
| EP3619236A1 (en) | 2020-03-11 |
| BR112019023097A2 (en) | 2020-07-28 |
| AU2018262156A1 (en) | 2019-11-28 |
| KR20200002889A (en) | 2020-01-08 |
| CA3061549A1 (en) | 2018-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201910027YA (en) | Bispecific antibody against ox40 and ctla-4 | |
| SG11201805422WA (en) | Multivalent and multispecific ox40-binding fusion proteins | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201908478SA (en) | Sterilisation method | |
| SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
| SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201903636PA (en) | Acoustic wave filter including two types of acoustic wave resonators | |
| SG11201900634VA (en) | Chimeric antigen receptor | |
| SG11201908820VA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201909646TA (en) | Trem2 antigen binding proteins and uses thereof | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201809669RA (en) | Use of glutamate modulating agents with immunotherapies to treat cancer | |
| SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201908088RA (en) | Antibodies against pd-l1 | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201807252QA (en) | Anti-lag-3 antibodies | |
| SG11201900501RA (en) | Cannabis composition | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201806322QA (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201403402VA (en) | Compounds | |
| SG11201806121PA (en) | Ror2 antibody compositions and related methods | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function |